Global Transcatheter Pulmonary Valve Market Size study & Forecast, by Application (Cardiac Anomaly, Pulmonary Atresia, Pulmonary Stenosis, Others), by Transcatheter Valve Technology (Balloon-Expanded, Self-Expanded), by End Use (Adult, Pediatric), by Tran

Global Transcatheter Pulmonary Valve Market Size study & Forecast, by Application (Cardiac Anomaly, Pulmonary Atresia, Pulmonary Stenosis, Others), by Transcatheter Valve Technology (Balloon-Expanded, Self-Expanded), by End Use (Adult, Pediatric), by Transcatheter Valve Raw Material (Synthetic, Tissue Engineered) and Regional Analysis, 2023-2030

Global Transcatheter Pulmonary Valve Market is valued approximately USD 43.99 Million in 2022 and is anticipated to grow with a healthy growth rate of more than 6.0% over the forecast period 2023-2030. A Transcatheter Pulmonary Valve is a medical device used in the field of interventional cardiology to treat certain heart conditions. This innovative valve is designed to be implanted without the need for open-heart surgery. It is typically used to replace a dysfunctional or damaged pulmonary valve in patients, most commonly those who have previously undergone surgical repair of congenital heart defects. The Transcatheter Pulmonary Valve Market is expanding because of factors such as increasing prevalence of various cardiovascular diseases, increasing incidences of congenital heart diseases (CHD) and rising demand for minimally invasive procedures.

As the prevalence of cardiac vascular diseases, including congenital heart defects, continues to rise due to factors such as an aging population, lifestyle choices, and improved diagnostic methods, the demand for innovative treatments such as Transcatheter Pulmonary Valves is expected to increase. Patients are increasingly seeking less invasive, safer, and more effective treatment options, which has spurred the growth of the market. For instance, the Centres for Disease Control and Prevention (CDC) 2022 report states that in 2020, 20.1 million persons aged 20 and older had coronary artery disease. Furthermore, the same report stated that every year about 805,000 Americans have a heart attack. Thus, rising chronic cardiac diseases are driving the market growth. Moreover, the National Library of Medicine announced in September 2022 that more than 200,000 heart valve replacement procedures are carried out annually worldwide, with an increase to 8,50,000 per year expected by 2050. These rising heart valve replacement procedures indicate the rising prevalence of cardiac vascular diseases which is further driving the market growth. In addition, rising technological advancement and favorable regulatory support are creating new opportunities for market growth. However, the availability of alternative technologies stifles market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Transcatheter Pulmonary Valve Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to factors such as the robust healthcare sector, coupled with a rising incidence of conditions such as pulmonary stenosis and regurgitation. Furthermore, the market is expected to expand owing to increased awareness, a growing appetite for cutting-edge heart valve solutions, and a rise in healthcare spending in the region. Whereas, Asia Pacific is projected to register the fastest growth owing to factors such as rising healthcare spending, rising prevalence of cardiac disorders, rising number of heart replacement surgery, favorable government policies for product development in the region,

Major market player included in this report are:
Boston Scientific Corporation
Braile Biomédica
CryoLife, Inc.
Edwards Lifesciences Corporation
JenaValve Technology, Inc
LivaNova PLC
Medtronic Plc
Venus Medtech Hangzhou Inc
Colibri Heart Valve, LLC
Xeltis AG

Recent Developments in the Market:
 In February 2023, Medtronic unveiled the re-launch of Harmony Transcatheter Pulmonary Valve (TPV) device This innovative solution is designed for patients dealing with congenital heart disease, , providing a minimally invasive alternative to open-heart surgery, specifically those with either a native or surgically repaired Right Ventricular Outflow Tract (RVOT). The Harmony TPV has been specifically developed to address severe pulmonary valve regurgitation in individuals with RVOT abnormalities, as outlined by the company.
 In May 2022, Venus Medtech's groundbreaking Transcatheter Pulmonic Valve Replacement (TPVR) technology, known as VenusP-ValveTM, achieved FDA approval for compassionate use in two cases. This approval, underscores the exceptional clinical benefits of VenusP-ValveTM. Distinguished by its dual flared ends, this technology enables stable anchoring and straightforward delivery, eliminating the need for pre-stenting before the procedure. VenusP-ValveTM is available in various specifications and boasts wide-ranging applicability, catering to the requirements of up to 85% of patients.

Global Transcatheter Pulmonary Valve Market Report Scope:
 Historical Data – 2020 - 2021
 Base Year for Estimation – 2022
 Forecast period - 2023-2030
 Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
 Segments Covered - Application, Transcatheter Valve Technology, End Use, Transcatheter Valve Raw Material, Region
 Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa


The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Application:
Cardiac Anomaly
Pulmonary Atresia
Pulmonary Stenosis
Pulmonary Regurgitation
Tetralogy of Fallot
Truncus Arteriosus
Others

By Transcatheter Valve Technology:
Balloon-Expanded
Self-Expanded

By End Use:
Adult
Pediatric

By Transcatheter Valve Raw Material:
Synthetic
Tissue Engineered

By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Companies Mentioned
Boston Scientific Corporation
Braile Biomédica
CryoLife, Inc.
Edwards Lifesciences Corporation
JenaValve Technology, Inc
LivaNova PLC
Medtronic Plc
Venus Medtech Hangzhou Inc
Colibri Heart Valve, LLC
Xeltis AG

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.